Top Markets
#1 Nesa Nesa +816.36%
#2 Cortex Cortex +69.03%
#3 Kinesis Silver Kinesis Silver +57.40%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.76%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 OpenEden OpenEden +19.32%
#8 Palladium Network Palladium Network +18.94%
#9 Cash Cat Cash Cat +18.07%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Shenzhen Salubris Pharmaceuticals Co., Ltd. Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294
Kedudukan dalam Saham #3529
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Harga Saham
$4.64
Modal Pasaran
$5.18B
Perubahan (1 hari)
0.41%
Perubahan (1 tahun)
-37.42%
Negara
CN
Perdagangan Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Kategori

Healthcare
Pendapatan untuk Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Shenzhen Salubris Pharmaceuticals Co., Ltd., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Shenzhen Salubris Pharmaceuticals Co., Ltd. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Intuitive Surgical, Inc. Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
ISRG.US
$3.81B -
US
EssilorLuxottica S.A. EssilorLuxottica S.A.
EssilorLuxottica S.A.
EL.PA
$4.11B -
FR
HOYA Corporation HOYA Corporation
HOYA Corporation
7741.T
- -
JP
Becton, Dickinson and Company Becton, Dickinson and Company
Becton, Dickinson and Company
BDX.US
$1.59B -
US
Alcon Inc. Alcon Inc.
Alcon Inc.
ALC.SW
- -
CH